BioCentury
ARTICLE | Company News

Helix, Moffitt explore data extraction and checkpoint inhibitors with L-DOS47

July 28, 2017 7:52 PM UTC

H. Lee Moffitt Cancer Center and Research Institute (Tampa, Fla.) and Helix BioPharma Corp (TSX:HBP) partnered in two separate deals concerning L-DOS47 from Helix.

The first deal involves the extraction of radiomics data from CT scans of late stage lung cancer patients treated with L-DOS47 in the Phase I LDOS002 trial. Helix said the data, which will be generated using Moffitt's HealthMyne platform, may identify a prognostic phenotype which Helix can incorporate in future clinical trials with L-DOS47. ...